Immunoenzymatic method for midkine determination in serum

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 2, 2006, Pages 247-252

  Krzystek Korpacka, Małgorzata ^a   Matusiewicz, Małgorzata ^a   Grabowski, Krzysztof ^a   Diakowska, Dorota ^a   Boehm, Dorota ^a   Kustrzeba Wójcicka, Irena ^a   Banaś, Teresa ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

ELISA; Growth factor; Midkine; Tumour marker

Indexed keywords

BIOTIN; HORSERADISH PEROXIDASE; MIDKINE; POLYCLONAL ANTIBODY; RECOMBINANT PROTEIN; STREPTAVIDIN; TETRAMETHYLBENZIDINE; TUMOR MARKER;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REFERENCE VALUE; RELIABILITY; SENSITIVITY ANALYSIS; SERUM;

ARMORACIA RUSTICANA; BOS;

EID: 33744790882     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Kadomatsu K, Huang R-P, Suganuma T, Murata F and Muramatsu T: A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis. J Cell Biol 1990, 110, 607-616.
2. Muramatsu T: Midkine and Pleiotrophin: Two Related Proteins Involved in Development, Survival, Inflammation and Tumorigenesis. J Biochem. 2002, 132, 359-371.
3. Yu GS, Hu J, Nakagawa H: Inhibition of b-amyloid cytotoxicity by midkine. Neurosci Lett 1998, 254, 125-128,
4. Callebaut C, Nisole S, Briand JP, Krust B, Hovanessian AG: Inhibition of HIV infection by the cytokine mid-kine. Virology 2001, 281, 248-264.
5. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R: An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997, 57, 1814-1819.
6. Garver RI Jr, Chan CS, Milner PG: Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993, 9, 463-466.
7. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG: Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994, 74, 1584-1590.
8. Aridome K, Tsutsui J, Takao S, Kadomatsu K, Ozawa M, Aikou T, Muramatsu T: Increased midkine gene expression in human gastrointestinal cancers. Jap J Cancer Res 1995, 86, 655-661.
9. Kato M, Maeta H, Kato S, Shinozawa T, Terada T: Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma. Mod Pathol 2000, 13, 1060-1065.
10. Kato S, Ishihara K, Shinozawa T, Yamaguchi H, Asano Y, Saito M, Kato M, Terada T, Awaya A, Hirano A, Dickson DW, Yen SH, Ohama E: Monoclonal antibody to human midkine reveals increased midkine expression in human brain tumors. J Neuropathol Exp Neurol 1999, 58, 430-441.
11. Qi M, Ikematsu S, Ichihara-Tanaka K, Sakuma S, Muramatsu T, Kadomatsu K: Midkine rescues Wilms' tumor cells from cisplatin-induced apoptosis: regulation of Bc1-2 expression by midkine. J Biochem 2000, 127, 269-277.
12. Nakagawara A, Milbrandt J, Muramatsu T, Deuel TF, Zhao H, Cnaan A, Brodeur GM: Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res 1995, 55, 1792-1797.
13. O'Brien T, Cranston D, Fuggle S, Bicknell R, Harris AL: The Angiogenic Factor Midkine Is Expressed in Bladder Cancer, and Overexpression Correlates with a Poor Outcome in Patients with Invasive, Cancers. Cancer Res 1996, 56, 2515-2518.
14. Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu T, Kurino T. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997, 233, 29-32.
15. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao, Y, Muramatsu T, Kadomatsu K: Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999, 57, 253-257.
16. Ye C, Qi M, Fan Q-W, Ito K, Akiyama S, Kasai Y, Matsuyama M, Muramatsu T, Kadomatsu K: Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999, 79, 179-184.
17. Ikematsu S, Yano A, Aridome, K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, Muramatsu H, Kadomatsu K, Muramatsu T: Serum midkine levels are increased in patients with various types of carcinomas. Br J Cancer 2000, 83, 701-706.
18. Shimada H, Nabeya Y, Tagawa M, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T: Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci 2003, 94, 628-632.
19. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Kadomatsu K, Muramatsu T, Ikematsu S, Sakuma S, Ochiai T: Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep 2003, 10, 411-414.
20. Obata Y, Kikuchi S, Lin Y, Yagyu K, Muramatsu T, Kumai H, Tokyo Research Group on Prevention of Gastric Cancer: Serum midkine concentrations and gastric cancer. Cancer Sci 2005, 96, 54-56.
21. Muramatsu H, Song X, Koide N, Hada H, Tsuji T, Kadomatsu K, Inui T, Kimura T, Sakakibara S, Muramatsu T: Enzyme-linked immunoassay for midkine and its application to evaluation of midkine levels in developing mouse brain and in sera from patients with hepatocellular carcinomas. J Biochem 1996, 119, 1171-1175.